1.
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 - 10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
2.
|
4 p, 551.6 KB |
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
/
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ;
Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ;
Raynaud, Sophie (Cote d'Azur University) ;
Cluzeau, Thomas (Cote d'Azur University) ;
Shih, Lee-Yung (Chang Gung University) ;
Tung-Liang, Chiang (Chang Gung University) ;
Ganster, Christina (University Medical Center Göttingen) ;
Shirneshan, Katayoon (University Medical Center Göttingen) ;
Haase, Detlef (University Medical Center Göttingen) ;
Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Trim, Nicola (Birmingham Women's Hospital) ;
Jeffries, Sally (Birmingham Women's Hospital) ;
Ridgway, Emma (Birmingham Women's Hospital) ;
Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449
|
|
3.
|
10 p, 1.1 MB |
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen. (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Cancer Center-Froedtert Hospital) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori,") ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Récher, Christian (Centre Hospitalier Universitaire de Toulouse) ;
Yoon, Sung Soo (Seoul National University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Chiba, Shigeru (University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital) ;
Hasabou, Nahla (Astellas Pharma US. Inc) ;
Lu, Qiaoyang (Astellas Pharma US. Inc) ;
Tiu, Ramon (Astellas Pharma US. Inc) ;
Levis, Mark (Johns Hopkins University) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation-positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). [...]
2022 - 10.1182/blood.2021011583
Blood, Vol. 139 Núm. 23 (june 2022) , p. 3366-3375
|
|
4.
|
7 p, 171.0 KB |
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
/
Rambaldi, Alessandro (Department of Oncology and Hematology. University of Milan) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Kantarjian, H. M. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Dombret, Hervé (Department of Hematology. Hopital Saint-Louis. Paris Diderot University) ;
Ottmann, O. G. (Division of Cancer and Genetics. School of Medicine. Cardiff University) ;
Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ;
Tuglus, C. A. (Amgen. Inc) ;
Zhao, X. (Amgen. Inc) ;
Kim, C. (Amgen. Inc) ;
Martinelli, Giovanni (Scientific Institute of Romagna for the Study and Treatment of Cancer) ;
Universitat Autònoma de Barcelona
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell-engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited treatment options. [...]
2020 - 10.1002/cncr.32558
Cancer, Vol. 126 Núm. 2 (15 2020) , p. 304-310
|
|
5.
|
13 p, 2.7 MB |
Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia
/
Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ;
Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ;
Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ;
Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Doubek, Michael (University Hospital Brno (República Txeca)) ;
Foà, Robin (Sapienza University of Rome) ;
Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ;
Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ;
Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Parovichnikova, Elena (National Research Center for Hematology, Moscow) ;
Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Schoonen, Marieke (Amgen Ltd, London) ;
Stieglmaier, Julia M. (Amgen GmBH, Munich) ;
Zugmaier, Gerhard (Amgen GmBH, Munich) ;
Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ;
Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348
|
|
6.
|
7 p, 444.1 KB |
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
/
Gökbuget, N. (Goethe University. University Hospital Frankfurt) ;
Kelsh, M. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Chia, V. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Advani, Anjali (Cleveland Clinic (Estats Units d'Amèrica)) ;
Bassan, Renato (Ospedale dell'Angelo (Venècia, Itàlia)) ;
Dombret, Hervé (Hôpital Saint-Louis (Paris, França)) ;
Doubek, Michael (University Hospital Brno (República Txeca)) ;
Fielding, A. K. (UCL Cancer Institute (Londres, Regne Unit)) ;
Giebel, S. (Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology (Polònia)) ;
Haddad, V. (Amgen Ltd. (Uxbridge, Regne Unit)) ;
Hoelzer, Dieter (Goethe University. University Hospital Frankfurt) ;
Holland, C. (Amgen Ltd. (Rockville, Estats Units d'Amèrica)) ;
Ifrah, N. (Centre Hospitalier Universitaire (Angers, França)) ;
Katz, A. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Maniar, T. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Martinelli, Giovanni (Policlinico Sant'Orsola-Malpighi (Bolònia, Itàlia)) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
O'Brien, Susan (University of Texas MD Anderson Cancer Center (Houston, Texas)) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rowe, J. M. (Rambam Medical Center) ;
Stein, Anthony (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Topp, M. (Universitätsklinikum Würzburg (Alemanya)) ;
Wadleigh, M. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Kantarjian, H. (University of Texas MD Anderson Cancer Center (Houston, Texas))
We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. [...]
2016 - 10.1038/bcj.2016.84
Blood Cancer Journal, Vol. 6, Núm. 9 (September 2016) , p. e473
|
|